Showing results (121-130 of 157) with videos related to
Sort By:
Pageof 16
Journal for Immunotherapy of Cancer|December 6, 2023
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trialAlex De Caluwe, Emanuela Romano, Philip Poortmans, et al.Plos One|July 26, 2016
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast CancerMichail Ignatiadis, Dimitrios Zardavas, Marc Lemort, et al.Nature Communications|November 26, 2025
Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 studyAndreas Papagiannis, Samira Majjaj, Francois P Duhoux, et al.Molecular Cancer Therapeutics|October 16, 2004
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelVirginie Durbecq, Marianne Paesmans, Fatima Cardoso, et al.The Lancet. Oncology|September 16, 2011
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient dataAngelo Di Leo, Christine Desmedt, John M S Bartlett, et al.Nature Communications|November 26, 2024
Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implicationsXiaoxiao Wang, David Venet, Frédéric Lifrange, et al.European Journal of Cancer (Oxford, England : 1990)|January 26, 2007
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)Rosa Giuliani, Virginie Durbecq, Angelo Di Leo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerAna M Gonzalez-Angulo, Jennifer K Litton, Kristine R Broglio, et al.Nature Medicine|June 25, 2026
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trialAlex De Caluwé, Isabelle Desmoulins, Kim Cao, et al.Journal of Pathology Informatics|December 9, 2021
A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot StudySarah N Dudgeon, Si Wen, Matthew G Hanna, et al.Pageof 16